Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

NCT05649722 is registered in ClinicalTrials.gov with Insmed Incorporated as lead sponsor.

NCT NCT05649722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05649722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term Use of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
Lead sponsor
Insmed Incorporated
Phase
Phase 2/3
Overall status
Completed
Start date
May 11, 2023
Completion date
April 1, 2026
Enrollment
31 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

interstitial lung disease, pulmonary hypertension